Giada Pinterpe
Overview
Explore the profile of Giada Pinterpe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciccarese C, Bauckneht M, Zagaria L, Fornarini G, Beccia V, Lanfranchi F, et al.
Target Oncol
. 2024 Nov;
20(1):103-112.
PMID: 39613950
Background: In recent years, theranostics has become a promising approach for treating metastatic castration-resistant prostate cancer (mCRPC), with trials investigating targeted radioligand therapy, particularly using prostate-specific membrane antigen labeled with...
2.
Strusi A, Pinterpe G, Ciccarese C, Pedone R, Sarcina M, Sardaro V, et al.
Expert Rev Anticancer Ther
. 2024 Jun;
24(8):661-664.
PMID: 38932631
The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant...
3.
Beccia V, Pinterpe G, Iacovelli R
Eur Urol
. 2024 Apr;
86(2):e44-e45.
PMID: 38644141
No abstract available.
4.
Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc J, Bouattour M, et al.
Eur J Cancer
. 2024 Feb;
200:113587.
PMID: 38340384
Background: Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world...
5.
Giampieri R, Baleani M, Bittoni A, Rastelli F, Catalano V, Del Prete M, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444451
Background: FLOT perioperative chemotherapy represents the standard of care in non-metastatic gastric cancer patients. Signet-ring cell positivity is associated with a worse prognosis in patients with gastric cancer treated with...
6.
Liguori C, Copparoni C, Felicetti C, Pecci F, Lupi A, Pinterpe G, et al.
Curr Oncol
. 2023 Jan;
30(1):1032-1045.
PMID: 36661728
Background: Unresectable cholangiocarcinoma prognosis can be extremely variable due to different symptoms and sites of disease involvement at diagnosis and unpredictable chemotherapy response rates. Most patients will usually receive 1st...
7.
Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230686
During the last decade, the identification of oncogenic driver mutations and the introduction of tyrosine kinase inhibitors (TKIs) in daily clinical practice have substantially revamped the therapeutic approach of oncogene-addicted,...
8.
Mentrasti G, Cantini L, Zichi C, DOstilio N, Gelsomino F, Martinelli E, et al.
Oncologist
. 2022 Jul;
27(9):e723-e730.
PMID: 35815922
Background: Coronavirus disease 2019 (COVID-19) has triggered the disruption of health care on a global scale. With Italy tangled up in the pandemic response, oncology care has been largely diverted...
9.
Bittoni A, Giampieri R, Pecci F, Pinterpe G, Mandolesi A, Del Prete M, et al.
Curr Oncol
. 2021 Sep;
28(5):3525-3536.
PMID: 34590611
Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin...
10.
Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, et al.
J Clin Med
. 2021 Apr;
10(7).
PMID: 33916569
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in cancer patients may vary widely dependent on the geographic area and this has significant implications for oncological care. The aim of...